ClinicalTrials.gg
CompletedNCT05103358Updated Oct 28, 2026Results posted

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 interventional study of nab-sirolimus in Tumor, Tumor, Solid and Metastasis, sponsored by Aadi Bioscience, Inc.. Completed at 166 sites in 3 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Primary conditionNeoplasm MetastasisRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm Metastasis
Why
  1. The study's listed conditions name Neoplasm Metastasis, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aadi Bioscience, Inc. · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Now CompletedResults posted+8 moreGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Study summary

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Read the detailed description

Study TSC-007 is a prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety profile of nab-sirolimus administered to patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Patients will be treated with single agent IV nab-sirolimus until disease progression, or unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion.

02

Conditions studied

  • Tumor
  • Tumor, Solid
  • Metastasis
  • Metastatic Cancer
  • Cancer
  • Cancer Metastatic
  • Tumors
  • Neoplasms
  • Neoplasm Metastasis
  • Solid Tumor
  • Advanced Solid Tumor
  • Advanced Cancer
  • Malignant Solid Tumor
  • Malignant Solid Neoplasm
  • Malignant Neoplasm
  • Malignant Tumor
  • TSC
  • TSC1
  • TSC2
  • Metastatic Solid Tumor
  • Metastatic Neoplasm

Browse trials for

Keywords

  • TSC1 gene
  • TSC2 gene
  • Tissue agnostic
  • Basket
  • nab-sirolimus
  • mTOR inhibitor
  • nanoparticle albumin bound
  • mammalian target of rapamycin
  • mechanistic target of rapamycin
  • tumor profile
  • tuberous sclerosis complex 1
  • tuberous sclerosis complex 2
  • mTOR
  • sirolimus
  • TSC1
  • TSC2
  • ABI-009
  • FYARRO
  • Precision
  • Precision 1
  • Pathogenic alterations
  • Pathogenic mutations
  • Inactivating mutations
03

In context

Neoplasm Metastasis Reclassified

4,040 studies on the registry are indexed under Neoplasm Metastasis; 886 are open to participants now.

This study's enrollment of 128 is above the median of 50 across 3,268 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Aadi Bioscience, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have a malignant solid tumor with a pathogenic inactivating TSC1 or TSC2 alteration. Genetic alterations should be identified using NGS in tumor tissue or liquid ).

    • Patients will be enrolled after the central evaluation of NGS report confirms eligibility.
  2. Patients must have solid tumors that are or locally advanced where surgical resection is not an option or likely to result in severe morbidity.
  3. Patients must have received all standard therapies appropriate for their tumor type and stage of disease or, in the opinion of the Investigator, the patient would be unlikely to tolerate or derive benefit from appropriate standard of care therapy, or the patient has no satisfactory alternative treatments.
  4. Patients must have 1 or more measurable target lesions by computed tomography (CT) scan or magnetic resonance imaging (MRI) ( v1.1).
  5. Age: 12 years or older.
  6. (ECOG) performance status 0 or 1 or Performance Status (KPS) ≥80 or Lansky play-performance scale for pediatric patients ≥80.
  7. Adequate liver function:

    1. Total ≤1.5 × (ULN) (unless due to Gilbert's syndrome, then ≤3 × ULN)
    2. (AST) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)
  8. Adequate renal function: ≥30 mL/min, Cockcroft-Gault CCr = ((140-age) × weight[kg]) / (72 × SCr[mL/min]) × 0.85, if female
  9. Adequate hematologic parameters:

    1. (ANC) ≥1.0 × 109/L (growth factor support allowed)
    2. count ≥100,000/mm3 (100 × 109/L) (transfusion and/or growth factor support allowed)
    3. ≥8.0 g/dL (transfusion and/or growth factor support allowed)
  10. Fasting serum triglyceride must be ≤300 mg/dL; fasting serum cholesterol must be ≤350 mg/dL.
  11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1.
  12. Male or non-pregnant and non-breastfeeding female:

    1. Females of must agree to use effective or abstinence without interruption from 28 days prior to starting product (IP) throughout 3 months after last dose of IP and have a negative serum pregnancy test (beta human chorionic gonadotropin, β-hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.
    2. Male patients must agree not to donate sperm and must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of IP. A second form of birth control is required even if he has undergone a successful vasectomy.
  13. The patient or the patient's parent(s) or legal guardian(s) understand(s) and sign(s) the .
  14. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with an mTOR inhibitor, including nab-sirolimus.
  2. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment.
  3. Patients with primary brain tumors or PEComa.
  4. Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:

    1. Patients with meningeal carcinomatosis, , spinal cord compression, untreated or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose [defined as dexamethasone 10 mg daily or higher] or increasing dose of systemic ) and without imminent need of radiation therapy are eligible. If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and/or complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment MRI scan should show no increase in brain lesion size/volume.
    2. Unstable angina pectoris, symptomatic congestive heart failure (, NYHA class III or IV), myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other cardiac disease.
    3. Pre-existing severely impaired lung function. If a patient has a pre-existing pulmonary condition, eligible patients should have a spirometry and diffusing capacity for carbon monoxide (DLCO) that is >50% of the normal predicted value and/or O2 saturation that is >88% at rest on room air (Note: spirometry and pulmonary function tests [PFTs] not required to be performed unless clinically indicated).
    4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy.
    5. A history of other than the one under treatment unless the patient is disease-free for more than 5 years from diagnosis. Note, controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low grade hematologic malignancies (eg CLL, follicular lymphoma, etc), or other adequately treated carcinoma-in-situ may be eligible, after discussion with the medical monitor.
    6. Uncontrolled hypertension (systolic blood pressure ≥160 mm-Hg and/or diastolic blood pressure ≥100 mm Hg).
    7. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
    8. Individuals with known (HIV) infection are excluded from this study as combination antiretroviral therapy could potentially result in significant pharmacokinetic interactions. In addition, these individuals are at increased risk of serious infections due to the effects of mTOR inhibition.
    9. Active or , with detectable viral load.
  5. Regarding concomitant medications with significant and P-gp interactions, discontinuation of strong inhibitors (eg, ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin, and others), strong inducers (eg, rifampin, rifabutin), and known CYP3A4 substrates with a narrow therapeutic window (eg, fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, or terfenadine) is required at least 5 half lives prior to receiving the first dose of nab-sirolimus, whichever is longer.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Arm A: Pathogenic inactivating TSC1 alterations

    Patients with pathogenic inactivating TSC1 alterations.

    Drug: nab-sirolimus

  • Experimental
    Arm B: Pathogenic inactivating TSC2 alterations

    Patients with pathogenic inactivating TSC2 alterations.

    Drug: nab-sirolimus

Interventions

  • Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients

    Also known as: ABI-009

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Based on CT or MRI scans from the time of study treatment initiation until disease progression, overall response rate (ORR) is defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by independent Radiographic Review (IRR). CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

    Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the number of months from the start of CR or PR (whichever response is recorded first) and subsequently confirmed to the first date of documented progressive disease (PD) or death using CT or MRI scans in accordance with RECIST v1.1. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions. PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.

  2. Disease Control Rate

    Disease control rate (DCR) is defined as BOR of confirmed CR or PR (either of any duration) or SD ≥12 weeks following study treatment initiation. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

    Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.

  3. Time to Response

    Time to response (TTR) is defined as the time from first dose of study drug to initial measurement of CR or PR, where CR or PR is subsequently confirmed. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

    Time frame: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.

  4. Progression-free Survival

    Number of months from study treatment initiation to the date of disease progression (PD) or death due to any cause PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From first dose of study treatment to the date of disease progression or death

  5. Overall Survival

    Number of months from study treatment initiation to the date of death due to any cause

    Time frame: From first dose of study treatment to the date of death

  6. Patient-Reported Outcome

    Changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QOQ-C30) v3.0 scores EORTC QOQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.

    Time frame: D1 of every cycle up to Cycle 24

  7. Incidence and Severity of Treatment-emergent and Treatment-related Adverse Events (AEs)

    Incidence and severity of treatment-emergent and treatment-related AEs as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.

07

Results

Posted Sep 28, 2026

Participant flow

Participants were enrolled from approximately 50 sites in the United States and globally (South Korea) . The first patient enrolled (consented) on 10 March 2022, with the last patient enrolled on 10 June 2024.

Participant flow — Overall Study
MilestoneArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Started6761
Completed00
Not completed6761
Withdrew: Withdrawal by subject138
Withdrew: Study terminated by sponsor2623
Withdrew: Lost to follow-up02
Withdrew: Death2626
Withdrew: Sponsor has closed the study. disease progression10
Withdrew: Disease progression10
Withdrew: Symptoms01
Withdrew: Discontinue nab-sirolimus01

Outcome measures

PrimaryOverall Response Rate (ORR)

Based on CT or MRI scans from the time of study treatment initiation until disease progression, overall response rate (ORR) is defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by independent Radiographic Review (IRR). CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

Time frame:
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.
Reported as:
Number · Percent of participants
Overall Response Rate (ORR)
Percent of participantsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Full Analysis Set9.0 (3.4 to 18.5)8.2 (2.7 to 18.1)
Efficacy Evaluable Set9.8 (3.7 to 20.2)8.9 (3.0 to 19.6)
SecondaryDuration of Response (DOR)

DOR is defined as the number of months from the start of CR or PR (whichever response is recorded first) and subsequently confirmed to the first date of documented progressive disease (PD) or death using CT or MRI scans in accordance with RECIST v1.1. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions. PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
Reported as:
Median · Months
Duration of Response (DOR)
MonthsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Full Analysis Set11.84 (9.47 to 15.23)13.62 (3.98 to 17.34)
Efficacy Evaluable Set11.84 (9.47 to 15.23)13.62 (3.98 to 17.34)
SecondaryDisease Control Rate

Disease control rate (DCR) is defined as BOR of confirmed CR or PR (either of any duration) or SD ≥12 weeks following study treatment initiation. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

Time frame:
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.
Reported as:
Number · Percent of participants
Disease Control Rate
Percent of participantsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Full Analysis Set34.3 (23.2 to 46.9)37.7 (25.6 to 51.0)
Efficacy Evaluable Set37.7 (25.6 to 51.0)41.1 (28.1 to 55.0)
SecondaryTime to Response

Time to response (TTR) is defined as the time from first dose of study drug to initial measurement of CR or PR, where CR or PR is subsequently confirmed. CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

Time frame:
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
Reported as:
Median · Months
Time to Response
MonthsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Full Analysis Set1.43 (1.28 to 2.80)2.66 (2.63 to 2.99)
Efficacy Evaluable Set1.43 (1.28 to 2.80)2.66 (2.63 to 2.99)
SecondaryProgression-free Survival

Number of months from study treatment initiation to the date of disease progression (PD) or death due to any cause PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From first dose of study treatment to the date of disease progression or death
Reported as:
Median · Months
Progression-free Survival
MonthsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Full Analysis Set4.8 (2.4 to 6.9)3.5 (1.9 to 5.6)
Efficacy Evaluable Set5.6 (2.8 to 6.9)4.0 (2.0 to 5.6)
SecondaryOverall Survival

Number of months from study treatment initiation to the date of death due to any cause

Time frame:
From first dose of study treatment to the date of death
Reported as:
Median · Months
Overall Survival
MonthsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Full Analysis Set12.4 (6.9 to 17.8)12.4 (3.5 to NA)
Efficacy Evaluable Set12.6 (7.4 to 17.8)12.4 (4.1 to NA)
SecondaryPatient-Reported Outcome

Changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QOQ-C30) v3.0 scores EORTC QOQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.

Time frame:
D1 of every cycle up to Cycle 24
Reported as:
Median · Scores on a scale
Patient-Reported Outcome
Scores on a scaleArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Global Health Status / QoL Baseline66.67 (0.0 to 91.7)66.67 (8.3 to 100.0)
Global Health Status / QoL C1D1—75.00 (75.0 to 75.0)
Global Health Status / QoL C2D166.67 (0.0 to 100.0)66.67 (16.7 to 100.0)
Global Health Status / QoL C3D166.67 (0.0 to 100.0)66.67 (0.0 to 100.0)
Global Health Status / QoL C4D166.67 (16.7 to 100.0)75.00 (50.0 to 100.0)
Global Health Status / QoL C5D166.67 (0.0 to 100.0)66.67 (16.7 to 100.0)
Global Health Status / QoL C6D175.0 (25.0 to 100.0)75.0 (25.0 to 91.7)
Global Health Status / QoL C7D175.0 (33.3 to 100.0)66.67 (33.3 to 100.0)
Global Health Status / QoL C8D175.0 (33.3 to 100.0)66.67 (50.0 to 100.0)
Global Health Status / QoL C9D175.0 (16.7 to 100.0)75.0 (33.3 to 100.0)
Global Health Status / QoL C10D166.67 (41.7 to 100.0)54.17 (41.7 to 100.0)
Global Health Status / QoL C11D183.33 (0.0 to 100.0)83.33 (50.0 to 100.0)
Global Health Status / QoL C12D183.33 (50.0 to 100.0)62.5 (41.7 to 100.0)
Global Health Status / QoL C13D191.67 (50.0 to 100.0)66.67 (58.3 to 83.3)
Global Health Status / QoL C14D191.67 (66.7 to 100.0)66.67 (50.0 to 91.7)
Global Health Status / QoL C15D191.67 (66.7 to 100.0)50.00 (33.3 to 66.7)
Global Health Status / QoL C16D175.00 (50.0 to 100.0)62.50 (0.0 to 83.3)
Global Health Status / QoL C17D179.17 (75.0 to 83.3)62.50 (8.3 to 83.3)
Global Health Status / QoL C18D175.00 (66.7 to 83.3)58.33 (33.3 to 91.7)
Global Health Status / QoL C19D183.3 (83.3 to 83.3)66.67 (50.0 to 83.3)
Global Health Status / QoL C20D183.3 (83.3 to 83.3)58.33 (33.3 to 83.3)
Global Health Status / QoL C21D179.17 (66.7 to 91.7)58.33 (33.3 to 83.3)
Global Health Status / QoL C22D183.34 (66.7 to 100.0)62.50 (33.3 to 91.7)
Global Health Status / QoL C23D187.50 (83.3 to 91.7)66.67 (50.0 to 83.3)
Global Health Status / QoL C24D187.50 (83.3 to 91.7)70.83 (58.3 to 83.3)
Physical Functioning / QoL Baseline80.00 (0 to 100.0)80.00 (13.3 to 100.0)
Physical Functioning / QoL C1D1—86.67 (86.67 to 86.67)
Physical Functioning / QoL C2D180.00 (6.7 to 100.0)73.33 (20.0 to 100.0)
Physical Functioning / QoL C3D186.67 (13.3 to 100.0)73.33 (26.7 to 100.0)
Physical Functioning / QoL C4D193.33 (13.3 to 100.0)80.0 (20.0 to 100.0)
Physical Functioning / QoL C5D193.33 (26.7 to 100.0)86.67 (25.0 to 100.0)
Physical Functioning / QoL C6D190.0 (6.7 to 100.0)86.67 (33.3 to 100.0)
Physical Functioning / QoL C7D193.33 (6.7 to 100.0)86.67 (33.3 to 100.0)
Physical Functioning / QoL C8D193.33 (6.7 to 100.0)86.67 (33.3 to 100.0)
Physical Functioning / QoL C9D196.67 (0.0 to 100.0)76.67 (60.0 to 100.0)
Physical Functioning / QoL C10D1100.0 (33.3 to 100.0)83.34 (60.0 to 100.0)
Physical Functioning / QoL C11D193.33 (33.3 to 100.0)80.00 (66.7 to 100.0)
Physical Functioning / QoL C12D193.34 (73.3 to 100.0)80.0 (73.3 to 100.0)
Physical Functioning / QoL C13D196.67 (66.7 to 100.0)80.0 (53.3 to 100.0)
Physical Functioning / QoL C14D193.34 (86.7 to 100.0)80.0 (80.0 to 100.0)
Physical Functioning / QoL C15D193.33 (86.7 to 100.0)80.0 (66.7 to 93.3)
Physical Functioning / QoL C16D186.67 (66.7 to 100.0)76.67 (6.7 to 100.0)
Physical Functioning / QoL C17D186.67 (60.0 to 93.3)73.34 (0.0 to 100.0)
Physical Functioning / QoL C18D196.67 (93.3 to 100.0)60.0 (6.7 to 100.0)
Physical Functioning / QoL C19D193.34 (86.7 to 100.0)90.0 (80.0 to 100.0)
Physical Functioning / QoL C20D1100.0 (100.0 to 100.0)93.34 (86.7 to 100.0)
Physical Functioning / QoL C21D196.67 (93.3 to 100.0)90.0 (80.0 to 100.0)
Physical Functioning / QoL C22D193.34 (86.7 to 100.0)90.0 (80.0 to 100.0)
Physical Functioning / QoL C23D193.34 (86.7 to 100.0)86.67 (73.3 to 100.0)
Physical Functioning / QoL C24D186.67 (86.67 to 86.7)90.0 (90.0 to 100.0)
Role Functioning / QoL Baseline83.33 (0.0 to 100.0)66.67 (0.0 to 100.0)
Role Functioning / QoL C1D1—100.0 (100.0 to 100.0)
Role Functioning / QoL C2D166.67 (0.0 to 100.0)75.00 (0.0 to 100.0)
Role Functioning / QoL C3D175.0 (0.0 to 100.0)66.67 (0.0 to 100.0)
Role Functioning / QoL C4D183.33 (0.0 to 100.0)83.33 (0.0 to 100.0)
Role Functioning / QoL C5D183.33 (0.0 to 100.0)83.33 (16.7 to 100.0)
Role Functioning / QoL C6D1100.0 (0.0 to 100.0)83.33 (0.0 to 100.0)
Role Functioning / QoL C7D1100.0 (0.0 to 100.0)83.33 (16.7 to 100.0)
Role Functioning / QoL C8D1100.0 (0.0 to 100.0)91.67 (33.3 to 100.0)
Role Functioning / QoL C9D191.67 (0.0 to 100.0)66.67 (66.67 to 100.0)
Role Functioning / QoL C10D1100.0 (16.7 to 100.0)100.0 (66.7 to 100.0)
Role Functioning / QoL C11D183.34 (0.0 to 100.0)100.0 (66.7 to 100.0)
Role Functioning / QoL C12D1100.0 (66.7 to 100.0)91.67 (83.3 to 100.0)
Role Functioning / QoL C13D191.67 (50.0 to 100.0)66.67 (66.67 to 100.0)
Role Functioning / QoL C14D1100.0 (66.7 to 100.0)100.0 (66.7 to 100.0)
Role Functioning / QoL C15D1100.0 (66.7 to 100.)83.33 (66.7 to 83.33)
Role Functioning / QoL C16D191.67 (66.7 to 100.0)83.34 (0.0 to 100.0)
Role Functioning / QoL C17D1100.0 (66.7 to 100.0)83.34 (0.0 to 100.0)
Role Functioning / QoL C18D183.34 (66.7 to 100.0)66.67 (0.0 to 100.0)
Role Functioning / QoL C19D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Role Functioning / QoL C20D1100.0 (100.0 to 100.0)91.67 (83.3 to 100.0)
Role Functioning / QoL C21D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Role Functioning / QoL C22D183.33 (83.33 to 83.33)83.34 (66.7 to 100.0)
Role Functioning / QoL C23D166.67 (66.67 to 66.67)83.34 (66.7 to 100.0)
Role Functioning / QoL C24D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Emotional Functioning / QoL Baseline83.33 (0.0 to 100.0)83.33 (41.7 to 100.0)
Emotional Functioning / QoL C1D1—75.0 (75.0 to 75.0)
Emotional Functioning / QoL C2D183.33 (0.0 to 100.0)91.67 (33.3 to 100.0)
Emotional Functioning / QoL C3D187.5 (0.0 to 100.0)83.33 (25.0 to 100.0)
Emotional Functioning / QoL C4D191.67 (50.0 to 100.0)91.67 (41.7 to 100.0)
Emotional Functioning / QoL C5D191.67 (33.3 to 100.0)83.33 (41.7 to 100.0)
Emotional Functioning / QoL C6D191.67 (50.0 to 100.0)91.67 (25.0 to 100.0)
Emotional Functioning / QoL C7D191.67 (0.0 to 100.0)100.00 (58.3 to 100.0)
Emotional Functioning / QoL C8D183.33 (66.7 to 100.0)83.33 (66.7 to 100.0)
Emotional Functioning / QoL C9D195.84 (33.3 to 100.0)91.67 (50.0 to 100.0)
Emotional Functioning / QoL C10D191.67 (66.7 to 100.0)83.33 (75.0 to 100.0)
Emotional Functioning / QoL C11D195.84 (66.7 to 100.0)83.33 (66.7 to 100.0)
Emotional Functioning / QoL C12D1100.0 (83.3 to 100.0)91.67 (66.7 to 100.0)
Emotional Functioning / QoL C13D1100.0 (83.3 to 100.0)83.33 (75.0 to 100.0)
Emotional Functioning / QoL C14D1100.0 (75.0 to 100.0)75.0 (75.0 to 100.0)
Emotional Functioning / QoL C15D1100.0 (66.7 to 100.0)75.0 (75.0 to 83.3)
Emotional Functioning / QoL C16D1100.0 (75.0 to 100.0)75.0 (33.3 to 100.0)
Emotional Functioning / QoL C17D175.00 (75.0 to 75.0)70.83 (50.0 to 100.0)
Emotional Functioning / QoL C18D187.5 (75.0 to 100.0)66.67 (8.3 to 100.0)
Emotional Functioning / QoL C19D195.84 (91.7 to 100.0)87.5 (75.0 to 100.0)
Emotional Functioning / QoL C20D183.34 (66.7 to 100.0)91.67 (83.3 to 100.0)
Emotional Functioning / QoL C21D187.5 (75.0 to 100.0)87.5 (75.0 to 100.0)
Emotional Functioning / QoL C22D195.84 (91.7 to 100.0)91.67 (83.3 to 100.0)
Emotional Functioning / QoL C23D175.00 (58.3 to 91.7)83.34 (66.7 to 100.0)
Emotional Functioning / QoL C24D170.83 (58.3 to 83.3)83.34 (66.7 to 100.0)
Cognitive Functioning / QoL Baseline83.33 (0.0 to 100.0)83.33 (33.3 to 100.0)
Cognitive Functioning / QoL C1D1—83.33 (83.33 to 83.33)
Cognitive Functioning / QoL C2D183.33 (0.0 to 100.0)83.33 (16.7 to 100.0)
Cognitive Functioning / QoL C3D183.33 (0.0 to 100.0)83.33 (16.7 to 100.0)
Cognitive Functioning / QoL C4D1100.00 (16.7 to 100.0)83.33 (33.3 to 100.0)
Cognitive Functioning / QoL C5D1100.00 (16.7 to 100.0)91.67 (16.7 to 100.0)
Cognitive Functioning / QoL C6D1100.00 (16.7 to 100.0)100.0 (33.3 to 100.0)
Cognitive Functioning / QoL C7D183.33 (0.0 to 100.0)100.0 (33.3 to 100.0)
Cognitive Functioning / QoL C8D1100.0 (50.0 to 100.0)83.33 (50.0 to 100.0)
Cognitive Functioning / QoL C9D1100.0 (33.3 to 100.0)91.67 (33.3 to 100.0)
Cognitive Functioning / QoL C10D1100.0 (33.3 to 100.0)91.67 (66.7 to 100.0)
Cognitive Functioning / QoL C11D1100.0 (33.3 to 100.0)66.67 (50.0 to 100.0)
Cognitive Functioning / QoL C12D1100.0 (83.3 to 100.0)91.67 (83.3 to 100.0)
Cognitive Functioning / QoL C13D1100.0 (66.7 to 100.0)83.33 (66.7 to 100.0)
Cognitive Functioning / QoL C14D1100.0 (100.0 to 100.0)91.67 (66.7 to 100.0)
Cognitive Functioning / QoL C15D1100.0 (83.3 to 100.0)83.33 (50.0 to 83.33)
Cognitive Functioning / QoL C16D1100.0 (100.0 to 100.0)66.67 (50.0 to 100.0)
Cognitive Functioning / QoL C17D1100.0 (100.0 to 100.0)91.67 (33.3 to 100.0)
Cognitive Functioning / QoL C18D1100.0 (100.0 to 100.0)66.67 (33.3 to 100.0)
Cognitive Functioning / QoL C19D1100.0 (100.0 to 100.0)75.0 (50.0 to 100.0)
Cognitive Functioning / QoL C20D1100.0 (100.0 to 100.0)91.67 (83.3 to 100.0)
Cognitive Functioning / QoL C21D1100.0 (100.0 to 100.0)91.67 (83.3 to 100.0)
Cognitive Functioning / QoL C22D1100.0 (100.0 to 100.0)91.67 (83.3 to 100.0)
Cognitive Functioning / QoL C23D191.67 (83.3 to 100.0)83.34 (66.7 to 100.0)
Cognitive Functioning / QoL C24D191.67 (83.3 to 100.0)83.34 (66.7 to 100.0)
Social Functioning / QoL Baseline66.67 (0.0 to 100.0)83.33 (0.0 to 100.0)
Social Functioning / QoL C1D1—100.0 (100.0 to 100.0)
Social Functioning / QoL C2D183.33 (0.0 to 100.0)83.33 (33.3 to 100.0)
Social Functioning / QoL C3D166.67 (0.0 to 100.0)83.33 (0.0 to 100.0)
Social Functioning / QoL C4D183.33 (0.0 to 100.0)83.33 (33.3 to 100.0)
Social Functioning / QoL C5D183.33 (0.0 to 100.0)91.67 (33.3 to 100.0)
Social Functioning / QoL C6D183.33 (33.3 to 100.0)83.33 (50.0 to 100.0)
Social Functioning / QoL C7D1100.0 (0.0 to 100.0)100.0 (33.3 to 100.0)
Social Functioning / QoL C8D1100.0 (33.3 to 100.0)100.0 (33.3 to 100.0)
Social Functioning / QoL C9D183.33 (16.7 to 100.0)100.0 (50.0 to 100.0)
Social Functioning / QoL C10D1100.0 (16.7 to 100.0)100.0 (66.7 to 100.0)
Social Functioning / QoL C11D191.67 (33.3 to 100.0)83.33 (66.7 to 100.0)
Social Functioning / QoL C12D191.67 (66.7 to 100.0)91.67 (66.7 to 100.0)
Social Functioning / QoL C13D1100.0 (66.7 to 100.0)66.67 (66.67 to 100.0)
Social Functioning / QoL C14D191.67 (66.7 to 100.0)66.67 (66.67 to 100.0)
Social Functioning / QoL C15D1100.0 (83.3 to 100.0)66.67 (66.67 to 83.3)
Social Functioning / QoL C16D191.67 (66.7 to 100.0)66.67 (16.7 to 100.0)
Social Functioning / QoL C17D191.67 (83.3 to 100.0)66.67 (0.0 to 100.0)
Social Functioning / QoL C18D183.34 (66.7 to 100.0)66.67 (0.0 to 100.0)
Social Functioning / QoL C19D191.67 (83.3 to 100.0)83.34 (66.7 to 100.0)
Social Functioning / QoL C20D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Social Functioning / QoL C21D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Social Functioning / QoL C22D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Social Functioning / QoL C23D183.34 (66.7 to 100.0)83.34 (66.7 to 100.0)
Social Functioning / QoL C24D191.67 (83.3 to 100.0)83.34 (66.7 to 100.0)
Fatigue / QoL Baseline33.33 (0.0 to 100.0)33.33 (0.0 to 100.0)
Fatigue / QoL C1D1—22.22 (22.22 to 22.22)
Fatigue / QoL C2D133.33 (0.0 to 100.0)33.33 (0.0 to 88.9)
Fatigue / QoL C3D133.33 (0.0 to 100.0)33.33 (0.0 to 100.0)
Fatigue / QoL C4D122.22 (0.0 to 100.0)33.33 (0.0 to 77.8)
Fatigue / QoL C5D122.22 (0.0 to 100.0)33.33 (0.0 to 77.8)
Fatigue / QoL C6D127.78 (0.0 to 100.0)33.33 (0.0 to 77.8)
Fatigue / QoL C7D133.33 (0.0 to 100.0)22.22 (11.1 to 66.7)
Fatigue / QoL C8D122.22 (0.0 to 100.0)27.78 (0.0 to 66.7)
Fatigue / QoL C9D122.22 (0.0 to 100.0)22.22 (0.0 to 33.3)
Fatigue / QoL C10D122.22 (0.0 to 66.7)22.22 (0.0 to 44.4)
Fatigue / QoL C11D116.67 (0.0 to 66.7)22.22 (0.0 to 66.7)
Fatigue / QoL C12D116.67 (0.0 to 44.4)11.11 (0.0 to 33.3)
Fatigue / QoL C13D111.11 (0.0 to 55.6)22.22 (0.0 to 33.3)
Fatigue / QoL C14D15.56 (0.0 to 33.3)22.22 (0.0 to 33.3)
Fatigue / QoL C15D122.22 (0.0 to 33.3)22.22 (22.2 to 33.3)
Fatigue / QoL C16D122.22 (11.1 to 33.3)22.22 (0.0 to 88.9)
Fatigue / QoL C17D133.33 (33.33 to 33.33)27.78 (0.0 to 88.9)
Fatigue / QoL C18D133.33 (22.2 to 44.4)33.33 (0.0 to 100.0)
Fatigue / QoL C19D127.78 (22.2 to 33.3)16.67 (0.0 to 33.3)
Fatigue / QoL C20D127.78 (22.2 to 33.3)16.67 (11.1 to 22.2)
Fatigue / QoL C21D127.78 (22.2 to 33.3)11.11 (0.0 to 22.2)
Fatigue / QoL C22D111.11 (0.0 to 22.2)16.67 (0.0 to 33.3)
Fatigue / QoL C23D122.22 (22.22 to 22.22)16.67 (0.0 to 33.3)
Fatigue / QoL C24D111.11 (0.0 to 22.2)16.67 (0.0 to 33.3)
Nausea / Vomiting / QoL Baseline0.00 (0.0 to 50.0)0.00 (0.0 to 100.0)
Nausea / Vomiting / QoL C1D1—0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C2D10.00 (0.0 to 100.0)0.00 (0.0 to 100.0)
Nausea / Vomiting / QoL C3D10.00 (0.0 to 100.0)0.00 (0.0 to 66.7)
Nausea / Vomiting / QoL C4D10.00 (0.0 to 66.7)0.00 (0.0 to 50.0)
Nausea / Vomiting / QoL C5D10.00 (0.0 to 33.3)0.00 (0.0 to 33.3)
Nausea / Vomiting / QoL C6D10.00 (0.0 to 33.3)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C7D10.00 (0.0 to 66.7)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C8D10.00 (0.0 to 33.3)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C9D10.00 (0.0 to 16.7)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C10D10.00 (0.0 to 16.7)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C11D10.00 (0.0 to 0.0)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C12D10.00 (0.0 to 33.3)0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C13D10.00 (0.0 to 16.7)0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C14D10.00 (0.0 to 0.0)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C15D10.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C16D10.00 (0.0 to 16.7)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C17D10.00 (0.0 to 16.7)0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C18D10.00 (0.0 to 0.0)0.00 (0.0 to 16.7)
Nausea / Vomiting / QoL C19D10.00 (0.0 to 0.0)16.67 (0.0 to 33.3)
Nausea / Vomiting / QoL C20D18.34 (0.0 to 16.7)8.34 (0.0 to 16.7)
Nausea / Vomiting / QoL C21D10.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C22D10.00 (0.0 to 0.0)0.00 (0.0 to 0.0)
Nausea / Vomiting / QoL C23D10.00 (0.0 to 0.0)8.34 (0.0 to 16.7)
Nausea / Vomiting / QoL C24D10.00 (0.0 to 0.0)8.34 (0.0 to 16.7)
Pain / QoL Baseline16.67 (0.0 to 100.0)16.67 (0.0 to 100.0)
Pain / QoL C1D1—0.00 (0.0 to 0.0)
Pain / QoL C2D133.33 (0.0 to 100.0)16.67 (0.0 to 100.0)
Pain / QoL C3D125.00 (0.0 to 100.0)16.67 (0.0 to 100.0)
Pain / QoL C4D116.67 (0.0 to 100.0)16.67 (0.0 to 100.0)
Pain / QoL C5D10.00 (0.0 to 66.7)16.67 (0.0 to 83.3)
Pain / QoL C6D18.34 (0.0 to 100.0)33.33 (0.0 to 83.3)
Pain / QoL C7D116.67 (0.0 to 100.0)33.33 (0.0 to 100.0)
Pain / QoL C8D10.00 (0.0 to 100.0)8.34 (0.0 to 83.3)
Pain / QoL C9D18.34 (0.0 to 100.0)8.34 (0.0 to 50.0)
Pain / QoL C10D10.00 (0.0 to 100.0)16.67 (0.0 to 33.3)
Pain / QoL C11D116.67 (0.0 to 33.3)33.33 (0.0 to 66.7)
Pain / QoL C12D18.34 (0.0 to 33.3)0.00 (0.0 to 33.3)
Pain / QoL C13D10.00 (0.0 to 33.3)33.33 (0.0 to 50.0)
Pain / QoL C14D10.00 (0.0 to 16.7)16.67 (0.0 to 33.3)
Pain / QoL C15D116.67 (0.0 to 33.3)33.33 (16.7 to 50.0)
Pain / QoL C16D10.00 (0.0 to 66.7)41.67 (0.0 to 100.0)
Pain / QoL C17D116.67 (0.0 to 33.3)33.33 (0.0 to 100.0)
Pain / QoL C18D18.34 (0.0 to 16.7)33.33 (0.0 to 100.0)
Pain / QoL C19D18.34 (0.0 to 16.7)16.67 (0.0 to 33.3)
Pain / QoL C20D116.67 (0.0 to 33.3)25.00 (0.0 to 50.0)
Pain / QoL C21D116.67 (0.0 to 33.3)8.34 (0.0 to 16.7)
Pain / QoL C22D18.34 (0.0 to 16.7)16.67 (0.0 to 33.3)
Pain / QoL C23D125.00 (0.0 to 50.0)25.00 (0.0 to 50.0)
Pain / QoL C24D125.00 (0.0 to 50.0)16.67 (0.0 to 33.3)
Dyspnoea / QoL Baseline0.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Dyspnoea / QoL C1D1—0.0 (0.0 to 0.0)
Dyspnoea / QoL C2D10.0 (0.0 to 66.7)0.0 (0.0 to 100.0)
Dyspnoea / QoL C3D10.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Dyspnoea / QoL C4D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Dyspnoea / QoL C5D10.0 (0.0 to 33.3)0.0 (0.0 to 100.0)
Dyspnoea / QoL C6D10.0 (0.0 to 100.0)0.0 (0.0 to 66.7)
Dyspnoea / QoL C7D10.0 (0.0 to 100.0)0.0 (0.0 to 66.7)
Dyspnoea / QoL C8D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Dyspnoea / QoL C9D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Dyspnoea / QoL C10D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Dyspnoea / QoL C11D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Dyspnoea / QoL C12D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C13D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C14D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C15D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C16D10.0 (0.0 to 33.3)16.67 (0.0 to 66.7)
Dyspnoea / QoL C17D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Dyspnoea / QoL C18D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C19D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C20D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Dyspnoea / QoL C21D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Dyspnoea / QoL C22D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Dyspnoea / QoL C23D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Dyspnoea / QoL C24D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Insomnia / QoL Baseline33.33 (0.0 to 100.0)33.33 (0.0 to 100.0)
Insomnia / QoL C1D1—0.0 (0.0 to 0.0)
Insomnia / QoL C2D133.33 (0.0 to 100.0)33.33 (0.0 to 100.0)
Insomnia / QoL C3D133.33 (0.0 to 100.0)33.33 (0.0 to 100.0)
Insomnia / QoL C4D133.33 (0.0 to 100.0)33.33 (0.0 to 66.7)
Insomnia / QoL C5D133.33 (0.0 to 100.0)0.0 (0.0 to 100.0)
Insomnia / QoL C6D10.0 (0.0 to 100.0)33.33 (0.0 to 66.7)
Insomnia / QoL C7D133.33 (0.0 to 100.0)33.33 (0.0 to 66.7)
Insomnia / QoL C8D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Insomnia / QoL C9D10.0 (0.0 to 100.0)33.33 (0.0 to 33.33)
Insomnia / QoL C10D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Insomnia / QoL C11D10.0 (0.0 to 66.7)0.0 (0.0 to 66.7)
Insomnia / QoL C12D10.0 (0.0 to 33.3)16.67 (0.0 to 33.3)
Insomnia / QoL C13D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Insomnia / QoL C14D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Insomnia / QoL C15D10.0 (0.0 to 33.3)33.33 (0.0 to 33.33)
Insomnia / QoL C16D116.67 (0.0 to 66.7)33.33 (0.0 to 100.0)
Insomnia / QoL C17D133.33 (33.33 to 33.33)16.67 (0.0 to 100.0)
Insomnia / QoL C18D116.67 (0.0 to 33.3)33.33 (0.0 to 66.7)
Insomnia / QoL C19D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Insomnia / QoL C20D133.33 (33.33 to 33.33)16.67 (0.0 to 33.3)
Insomnia / QoL C21D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Insomnia / QoL C22D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Insomnia / QoL C23D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Insomnia / QoL C24D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Appetite Loss / QoL Baseline0.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Appetite Loss / QoL C1D1—0.0 (0.0 to 0.0)
Appetite Loss / QoL C2D133.3 (0.0 to 100.0)33.33 (0.0 to 100.0)
Appetite Loss / QoL C3D133.33 (0.0 to 100.0)0.0 (0.0 to 100.0)
Appetite Loss / QoL C4D116.67 (0.0 to 100.0)0.0 (0.0 to 100.0)
Appetite Loss / QoL C5D133.33 (0.0 to 66.7)0.0 (0.0 to 100.0)
Appetite Loss / QoL C6D10.0 (0.0 to 66.7)0.0 (0.0 to 66.7)
Appetite Loss / QoL C7D10.0 (0.0 to 66.7)0.0 (0.0 to 66.7)
Appetite Loss / QoL C8D10.0 (0.0 to 66.7)0.0 (0.0 to 100.0)
Appetite Loss / QoL C9D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Appetite Loss / QoL C10D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Appetite Loss / QoL C11D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Appetite Loss / QoL C12D10.0 (0.0 to 66.7)0.0 (0.0 to 0.0)
Appetite Loss / QoL C13D10.0 (0.0 to 66.7)0.0 (0.0 to 0.0)
Appetite Loss / QoL C14D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Appetite Loss / QoL C15D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Appetite Loss / QoL C16D116.67 (0.0 to 33.3)16.67 (0.0 to 33.3)
Appetite Loss / QoL C17D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Appetite Loss / QoL C18D116.67 (0.0 to 33.3)0.0 (0.0 to 33.3)
Appetite Loss / QoL C19D116.67 (0.0 to 33.3)16.67 (0.0 to 33.3)
Appetite Loss / QoL C20D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Appetite Loss / QoL C21D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Appetite Loss / QoL C22D116.67 (0.0 to 33.3)16.67 (0.0 to 33.3)
Appetite Loss / QoL C23D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Appetite Loss / QoL C24D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Constipation / QoL Baseline0.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Constipation / QoL C1D1—0.0 (0.0 to 0.0)
Constipation / QoL C2D10.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Constipation / QoL C3D10.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Constipation / QoL C4D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Constipation / QoL C5D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Constipation / QoL C6D10.0 (0.0 to 66.7)0.0 (0.0 to 33.3)
Constipation / QoL C7D10.0 (0.0 to 66.7)0.0 (0.0 to 33.3)
Constipation / QoL C8D10.0 (0.0 to 33.3)0.0 (0.0 to 66.7)
Constipation / QoL C9D10.0 (0.0 to 66.7)0.0 (0.0 to 66.7)
Constipation / QoL C10D10.0 (0.0 to 66.7)0.0 (0.0 to 33.3)
Constipation / QoL C11D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Constipation / QoL C12D10.0 (0.0 to 66.7)0.0 (0.0 to 33.3)
Constipation / QoL C13D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Constipation / QoL C14D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Constipation / QoL C15D10.0 (0.0 to 0.0)33.33 (0.0 to 66.7)
Constipation / QoL C16D116.67 (0.0 to 33.3)16.67 (0.0 to 33.3)
Constipation / QoL C17D10.0 (0.0 to 0.0)0.0 (0.0 to 66.7)
Constipation / QoL C18D116.67 (0.0 to 33.3)0.0 (0.0 to 66.7)
Constipation / QoL C19D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Constipation / QoL C20D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Constipation / QoL C21D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Constipation / QoL C22D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Constipation / QoL C23D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Constipation / QoL C24D116.67 (0.0 to 33.3)16.67 (0.0 to 33.3)
Diarhoea / QoL Baseline0.0 (0.0 to 100.0)0.0 (0.0 to 66.7)
Diarhoea / QoL C1D1—0.0 (0.0 to 0.0)
Diarhoea / QoL C2D10.0 (0.0 to 66.7)0.0 (0.0 to 100.0)
Diarhoea / QoL C3D10.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Diarhoea / QoL C4D10.0 (0.0 to 66.7)33.33 (0.0 to 66.7)
Diarhoea / QoL C5D10.0 (0.0 to 66.7)0.0 (0.0 to 33.3)
Diarhoea / QoL C6D10.0 (0.0 to 66.7)0.0 (0.0 to 33.3)
Diarhoea / QoL C7D10.0 (0.0 to 33.3)0.0 (0.0 to 66.7)
Diarhoea / QoL C8D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Diarhoea / QoL C9D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Diarhoea / QoL C10D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Diarhoea / QoL C11D10.0 (0.0 to 0.0)0.0 (0.0 to 33.3)
Diarhoea / QoL C12D10.0 (0.0 to 0.0)0.0 (0.0 to 33.3)
Diarhoea / QoL C13D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Diarhoea / QoL C14D10.0 (0.0 to 0.0)0.0 (0.0 to 33.3)
Diarhoea / QoL C15D10.0 (0.0 to 33.3)0.0 (0.0 to 0.0)
Diarhoea / QoL C16D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Diarhoea / QoL C17D10.0 (0.0 to 0.0)0.0 (0.0 to 33.3)
Diarhoea / QoL C18D116.67 (0.0 to 33.3)0.0 (0.0 to 66.7)
Diarhoea / QoL C19D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Diarhoea / QoL C20D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Diarhoea / QoL C21D133.34 (0.0 to 66.7)16.67 (0.0 to 33.3)
Diarhoea / QoL C22D10.0 (0.0 to 0.0)33.34 (0.0 to 66.7)
Diarhoea / QoL C23D116.67 (0.0 to 33.3)33.34 (0.0 to 66.7)
Diarhoea / QoL C24D10.0 (0.0 to 0.0)16.67 (0.0 to 33.3)
Financial Problems / QoL Baseline0.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Financial Problems / QoL C1D1—0.0 (0.0 to 0.0)
Financial Problems / QoL C2D10.0 (0.0 to 100.0)0.0 (0.0 to 66.7)
Financial Problems / QoL C3D10.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Financial Problems / QoL C4D10.0 (0.0 to 100.0)0.0 (0.0 to 100.0)
Financial Problems / QoL C5D10.0 (0.0 to 100.0)16.67 (0.0 to 100.0)
Financial Problems / QoL C6D10.0 (0.0 to 100.0)0.0 (0.0 to 66.7)
Financial Problems / QoL C7D10.0 (0.0 to 100.0)0.0 (0.0 to 33.3)
Financial Problems / QoL C8D10.0 (0.0 to 33.3)0.0 (0.0 to 100.0)
Financial Problems / QoL C9D10.0 (0.0 to 66.7)0.0 (0.0 to 66.7)
Financial Problems / QoL C10D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Financial Problems / QoL C11D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Financial Problems / QoL C12D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Financial Problems / QoL C13D10.0 (0.0 to 33.3)0.0 (0.0 to 66.7)
Financial Problems / QoL C14D10.0 (0.0 to 33.3)16.67 (0.0 to 33.3)
Financial Problems / QoL C15D10.0 (0.0 to 0.0)0.0 (0.0 to 33.3)
Financial Problems / QoL C16D10.0 (0.0 to 33.3)0.0 (0.0 to 33.3)
Financial Problems / QoL C17D10.0 (0.0 to 0.0)0.0 (0.0 to 33.3)
Financial Problems / QoL C18D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Financial Problems / QoL C19D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Financial Problems / QoL C20D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Financial Problems / QoL C21D10.0 (0.0 to 0.0)0.0 (0.0 to 0.0)
Financial Problems / QoL C22D116.67 (0.0 to 33.3)0.0 (0.0 to 0.0)
Financial Problems / QoL C23D133.34 (0.0 to 66.7)0.0 (0.0 to 0.0)
Financial Problems / QoL C24D133.34 (0.0 to 66.7)0.0 (0.0 to 0.0)
SecondaryIncidence and Severity of Treatment-emergent and Treatment-related Adverse Events (AEs)

Incidence and severity of treatment-emergent and treatment-related AEs as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

Time frame:
Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.
Reported as:
Count of participants · Participants
Incidence and Severity of Treatment-emergent and Treatment-related Adverse Events (AEs)
ParticipantsArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Any TEAEs6761
Any related TEAEs6055
Any treatment-emergent SAEs3529
Any treatment-emergent related SAEs1210
Any Grade 3 or 4 TEAEs5044
Any Grade 3 or 4 related TEAEs3732

Adverse events

Collected over Monitored continuously with onset on or after the first dose of study drug through last dose of study drug (estimated up to 30 months) plus safety follow-up of 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Pathogenic Inactivating TSC1 Alterations26/67 (38.8%)35/67 (52.2%)67/67 (100%)
Arm B: Pathogenic Inactivating TSC2 Alterations26/61 (42.6%)29/61 (47.5%)61/61 (100%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
Urinary tract infectionInfections and infestations5/670/61
Acute kidney injuryRenal and urinary disorders3/674/61
PneumoniaInfections and infestations3/672/61
SepsisInfections and infestations3/672/61
Pleural effusionRespiratory, thoracic and mediastinal disorders3/671/61
NauseaGastrointestinal disorders1/672/61
COVID-19 pneumoniaInfections and infestations2/670/61
Abdominal painGastrointestinal disorders2/671/61
ConstipationGastrointestinal disorders2/670/61
PneumonitisRespiratory, thoracic and mediastinal disorders2/670/61
Most frequent other events
Showing 10 of 74
Most frequent other events
EventArm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 Alterations
AnaemiaBlood and lymphatic system disorders32/6710/61
FatigueGeneral disorders30/6724/61
Decreased appetiteMetabolism and nutrition disorders28/6712/61
NauseaGastrointestinal disorders25/6719/61
DiarrhoeaGastrointestinal disorders24/6717/61
StomatitisGastrointestinal disorders21/6718/61
HypokalaemiaMetabolism and nutrition disorders21/6713/61
Weight decreasedInvestigations18/6711/61
DysgeusiaNervous system disorders18/678/61
ConstipationGastrointestinal disorders17/6714/61

Baseline characteristics

Age, Customized
Age, Customized(Participants)Arm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 AlterationsTotal
Age — <65 years343468
Age — 65-74 years231841
Age — > = 75 years10919
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 AlterationsTotal
Female413677
Male262551
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 AlterationsTotal
Hispanic or Latino4812
Not Hispanic or Latino6153114
Unknown or Not Reported202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Pathogenic Inactivating TSC1 AlterationsArm B: Pathogenic Inactivating TSC2 AlterationsTotal
Race — White464591
Race — Asian131326
Race — Not Applicable426
Race — Black or African American314
Race — Other101
08

Study locations

166 sites
  • Alabama Oncology
    Birmingham, Alabama 35243, United States
  • Southern Cancer Center
    Mobile, Alabama 36607, United States
  • Arizona Oncology Associates
    Goodyear, Arizona 85395, United States
  • Honor Health
    Phoenix, Arizona 85016, United States
  • Arizona Oncology Associates
    Prescott Valley, Arizona 86301, United States
  • Yuma Regional Medical Center
    Yuma, Arizona 85364, United States
  • PCR Oncology
    Arroyo Grande, California 93420, United States
  • Nextgen Oncology
    Beverly Hills, California 90212, United States
  • City of Hope
    Duarte, California 91010, United States
  • Providence Medical Foundation (Fullerton)
    Fullerton, California 92835, United States
  • MemorialCare
    Long Beach, California 90806, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • UCLA - Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • Providence Medical Foundation (Napa)
    Napa, California 94558, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • Sharp HealthCare
    San Diego, California 92123, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94115, United States
  • Ridley-Tree Cancer Center
    Santa Barbara, California 93105, United States
  • Sarcoma Oncology Research Center
    Santa Monica, California 90403, United States
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • The Oncology Institute of Hope & Innovation
    Whittier, California 90602, United States
  • Rocky Mountain Cancer Centers
    Aurora, Colorado 80012, United States
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers (Williams St)
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80220, United States
  • Rocky Mountain Cancer Centers
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer Centers
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer Centers
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers
    Thornton, Colorado 80260, United States
  • Hartford Healthcare
    Hartford, Connecticut 06102, United States
  • Eastern Connecticut Hematology and Oncology
    Norwich, Connecticut 06360, United States
  • Florida Cancer Specialists - North Division
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialists - South Division
    Bonita Springs, Florida 34135, United States
  • Florida Cancer Specialists - South Division
    Bradenton, Florida 34205, United States
  • Florida Cancer Specialists - South Division
    Bradenton, Florida 34211, United States
  • Florida Cancer Specialists - North Division
    Brandon, Florida 33511, United States
  • Florida Cancer Specialists - South Division
    Cape Coral, Florida 33909, United States
  • Florida Cancer Specialists - North Division
    Clearwater, Florida 33761, United States
  • Cancer Specialist - East
    Daytona Beach, Florida 32117, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Florida Cancer Specialists South Division
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists - South
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialists - South
    Fort Myers, Florida 33908, United States
  • Florida Cancer Specialists - North Division
    Gainesville, Florida 32605, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • The Oncology Institute of Hope and Innovation
    Lakeland, Florida 33812, United States
  • TOI Florida
    Lakeland, Florida 33812, United States
  • Florida Cancer Specialists - North Division
    Largo, Florida 33770, United States
  • Florida Cancer Specialists - North Division
    Lecanto, Florida 34461, United States
  • Florida Cancer Specialists - South Division
    Naples, Florida 34102, United States
  • Florida Cancer Specialists - North Division
    Ocala, Florida 34474, United States
  • Ocala Oncology
    Ocala, Florida 34474, United States
  • Florida Cancer Specialists - North Division
    Orange City, Florida 32763, United States
  • Florida Cancer Specialists - North Division
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists - South Division
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists - South Division
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists - South Division
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists and Research Institute - North Division
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists - North
    St. Petersburg, Florida 33707, United States
  • Florida Cancer Specialist - East
    Stuart, Florida 34994, United States
  • Florida Cancer Specialists - North Division
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists - North Division
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists - North Division
    Trinity, Florida 34655, United States
  • Florida Cancer Specialists - South Division
    Venice, Florida 34285, United States
  • Florida Cancer Specialists - South Division
    Venice, Florida 34292, United States
  • Florida Cancer Specialists - East
    Vero Beach, Florida 32960, United States
  • Florida Cancer Specialists - East
    Wellington, Florida 33414, United States
  • Florida Cancer Specialists - East
    West Palm Beach, Florida 33401, United States
  • Morehouse School of Medicine
    Atlanta, Georgia 30303, United States
  • Hawaii Cancer Center
    Honolulu, Hawaii 96813, United States
  • Hope and Healing Cancer Services
    Hinsdale, Illinois 60521, United States
  • Northwest Oncology and Hematology
    Rolling Meadows, Illinois 60008, United States
  • Urology of Indiana
    Carmel, Indiana 46032, United States
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46804, United States
  • Goshen Health
    Goshen, Indiana 46526, United States
  • Our Lady of the Lake
    Baton Rouge, Louisiana 70817, United States
  • Pontchartrain
    Hammond, Louisiana 70403, United States
  • American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)
    Bethesda, Maryland 20817, United States
  • Frederick Health
    Frederick, Maryland 21702, United States
  • Maryland Oncology Hematology
    Rockville, Maryland 20850, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Southcoast Centers for Cancer Care
    Fairhaven, Massachusetts 02719, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Sparrow Hospital
    Lansing, Michigan 48912, United States
  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55404, United States
  • Central Care Cancer Center
    Bolivar, Missouri 65613, United States
  • Lake Regional
    Osage Beach, Missouri 65065, United States
  • Mosaic Life Care
    Saint Joseph, Missouri 64507, United States
  • Oncology Hematology Associates
    Springfield, Missouri 65807, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Nebraska Cancer Specialists
    Grand Island, Nebraska 68803, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • OptumCare Cancer Care-Parent
    Las Vegas, Nevada 89102, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New Jersey Cancer Care and Blood Disorders
    Belleville, New Jersey 07109, United States
  • Englewood Hospital and Medical Center
    Englewood, New Jersey 07631, United States

Showing the first 100 of 166 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Sep 28, 2026
Results
Results posted
posted Sep 28, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (3 United States, 1 Puerto Rico)
  • Florida Cancer Specialists and Research Institute - North Division · St. Petersburg, United States
  • Florida Cancer Specialists - North · St. Petersburg, United States
  • Washington University School of Medicine · St Louis, United States
  • Pan Oncology Trials, LLC · San Juan, Puerto Rico
Show 4 removed
  • Florida Cancer Specialists and Research Institute - North Division · Saint Petersburg, United States
  • Florida Cancer Specialists - North · Saint Petersburg, United States
  • Washington University School of Medicine · Saint Louis, United States
  • Pan Oncology Trials, LLC · San Juan, Puerto Rico
Sep 28, 2026
Start date
Feb 15, 2022→Mar 10, 2022
Sep 28, 2026
Primary completion
Dec 31, 2024→Dec 23, 2024 (actual)
Sep 28, 2026
Study completion
Dec 31, 2025→Dec 23, 2024 (actual)
Sep 28, 2026
Enrollment
120 (estimated)→128 (actual)
Sep 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedOverall response rateResponse Rate (ORR)Time frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.
Sep 28, 2026
Documents
Secondary outcomes
7 edited
What changed in the outcomes
  • EditedDuration of responseResponse (DOR)Time frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
  • EditedDisease control rateControl RateTime frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.
  • EditedTime to responseResponseTime frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
  • EditedProgression-free survivalSurvivalTime frame: 9 months → From first dose of study treatment to the date of disease progression or death
  • EditedOverall survivalSurvivalTime frame: 24 months → From first dose of study treatment to the date of death
  • EditedPatient-reported outcomeReported OutcomeTime frame: 9 months → D1 of every cycle up to Cycle 24
  • EditedIncidence and severitySeverity of treatmentTreatment-emergent and treatmentTreatment-related adverse eventsAdverse Events (AEs)Time frame: 9 months → Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Active, not recruiting→Completed
    Results posted
    4 sites added, 4 sites removed
    Show 4 added (3 United States, 1 Puerto Rico)
    • Florida Cancer Specialists and Research Institute - North Division · St. Petersburg, United States
    • Florida Cancer Specialists - North · St. Petersburg, United States
    • Washington University School of Medicine · St Louis, United States
    • Pan Oncology Trials, LLC · San Juan, Puerto Rico
    Show 4 removed
    • Florida Cancer Specialists and Research Institute - North Division · Saint Petersburg, United States
    • Florida Cancer Specialists - North · Saint Petersburg, United States
    • Washington University School of Medicine · Saint Louis, United States
    • Pan Oncology Trials, LLC · San Juan, Puerto Rico
    Start date Feb 15, 2022→Mar 10, 2022
    Primary completion Dec 31, 2024→Dec 23, 2024 (now actual)
    Study completion Dec 31, 2025→Dec 23, 2024 (now actual)
    Enrollment 120 (estimated)→128 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedOverall response rateResponse Rate (ORR)Time frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.
    Secondary outcomes 7 edited
    What changed in the outcomes
    • EditedDuration of responseResponse (DOR)Time frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
    • EditedDisease control rateControl RateTime frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.
    • EditedTime to responseResponseTime frame: 9 months → The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
    • EditedProgression-free survivalSurvivalTime frame: 9 months → From first dose of study treatment to the date of disease progression or death
    • EditedOverall survivalSurvivalTime frame: 24 months → From first dose of study treatment to the date of death
    • EditedPatient-reported outcomeReported OutcomeTime frame: 9 months → D1 of every cycle up to Cycle 24
    • EditedIncidence and severitySeverity of treatmentTreatment-emergent and treatmentTreatment-related adverse eventsAdverse Events (AEs)Time frame: 9 months → Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05103358
Lead sponsor
Aadi Bioscience, Inc.
Responsible party
Sponsor
First posted
Nov 2, 2021
Start date
Mar 10, 2022
Primary completion
Dec 23, 2024
Completion
Dec 23, 2024
Results posted
Sep 28, 2026
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus Albumin-bound Nanoparticles

Start the discussion